Apimeds Pharmaceuticals US (APUS) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $4.39, -4.15% vs the prior close of $4.58.
- Volume 109.00K shares, 0.0x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
APUS slides 4.1% to $4.39, 3 down days in a row. Closed at $4.39, -4.15% vs the prior close of $4.58. Day range $4.00–$4.41, opened at $4.25.
APUS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — APUS slides 4.1% to $4.39, 3 down days in a row
- Closed at $4.39, -4.15% vs the prior close of $4.58. Day range $4.00–$4.41, opened at $4.25.
- Volume was 109.00K shares, 0.0x its 50-day average of 4.79M — lighter than usual.
- Price is +10.7% vs its 50-day average ($3.97) and -62.4% vs its 200-day average ($11.67).
- 52-week range $1.51–$59.70; today's close sits at 5% of that range, 92.6% below the 52-week high.
- That makes 3 straight losses.
Oct 14, 2026 — APUS dips 0.9% to $4.58
- Closed at $4.58, -0.87% vs the prior close of $4.62. Day range $4.25–$4.81, opened at $4.60.
- Volume was 235.30K shares, 0.0x its 50-day average of 4.79M — lighter than usual.
- Price is +15.3% vs its 50-day average ($3.97) and -61.0% vs its 200-day average ($11.73).
- 52-week range $1.51–$59.70; today's close sits at 5% of that range, 92.3% below the 52-week high.
Oct 13, 2026 — APUS slides 11.2% to $4.62
- Closed at $4.62, -11.15% vs the prior close of $5.20. Day range $4.26–$4.91, opened at $4.87.
- Volume was 339.80K shares, 0.1x its 50-day average of 4.78M — lighter than usual.
- Price is +16.1% vs its 50-day average ($3.98) and -60.8% vs its 200-day average ($11.79).
- 52-week range $1.51–$59.70; today's close sits at 5% of that range, 92.3% below the 52-week high.
- SEC filings that day: 8-K.
Oct 12, 2026 — APUS jumps 3.6% to $5.20
- Closed at $5.20, +3.59% vs the prior close of $5.02. Day range $4.97–$6.04, opened at $5.43.
- Volume was 1.39M shares, 0.3x its 50-day average of 4.75M — lighter than usual.
- Price is +30.6% vs its 50-day average ($3.98) and -56.2% vs its 200-day average ($11.86).
- 52-week range $1.51–$59.70; today's close sits at 6% of that range, 91.3% below the 52-week high.
Oct 9, 2026 — APUS slides 8.9% to $5.02, 3 down days in a row
- Closed at $5.02, -8.89% vs the prior close of $5.51. Day range $4.40–$5.72, opened at $5.54.
- Volume was 3.35M shares, 0.7x its 50-day average of 4.69M.
- Price is +26.1% vs its 50-day average ($3.98) and -57.9% vs its 200-day average ($11.92).
- 52-week range $1.51–$59.70; today's close sits at 6% of that range, 91.6% below the 52-week high.
- That makes 3 straight losses.
Oct 8, 2026 — APUS slides 21.8% to $5.51
- Closed at $5.51, -21.84% vs the prior close of $7.05. Day range $5.21–$6.50, opened at $6.43.
- Volume was 1.11M shares, 0.2x its 50-day average of 4.67M — lighter than usual.
- Price is +38.5% vs its 50-day average ($3.98) and -54.0% vs its 200-day average ($11.98).
- 52-week range $1.51–$59.70; today's close sits at 7% of that range, 90.8% below the 52-week high.
Oct 7, 2026 — APUS dips 1.1% to $7.05 on 5.3x normal volume
- Closed at $7.05, -1.12% vs the prior close of $7.13. Day range $6.86–$9.84, opened at $8.00.
- Volume was 22.40M shares, 5.3x its 50-day average of 4.23M — unusually heavy trading.
- Price is +76.9% vs its 50-day average ($3.98) and -41.4% vs its 200-day average ($12.03).
- 52-week range $1.51–$59.70; today's close sits at 10% of that range, 88.2% below the 52-week high.
Oct 6, 2026 — APUS jumps 55.3% to $7.13 on 13.1x normal volume
- Closed at $7.13, +55.34% vs the prior close of $4.59. Day range $4.71–$8.39, opened at $4.91.
- Volume was 43.84M shares, 13.1x its 50-day average of 3.35M — unusually heavy trading.
- Price is +78.1% vs its 50-day average ($4.00) and -41.0% vs its 200-day average ($12.08).
- 52-week range $1.51–$59.70; today's close sits at 10% of that range, 88.1% below the 52-week high.
Oct 5, 2026 — APUS jumps 42.5% to $4.59 on 12.6x normal volume
- Closed at $4.59, +42.55% vs the prior close of $3.22. Day range $4.21–$5.83, opened at $4.99.
- Volume was 33.79M shares, 12.6x its 50-day average of 2.68M — unusually heavy trading.
- Price is +15.1% vs its 50-day average ($3.99) and -62.2% vs its 200-day average ($12.14).
- 52-week range $1.51–$59.70; today's close sits at 5% of that range, 92.3% below the 52-week high.
Oct 2, 2026 — APUS slides 21.5% to $3.22, 5 down days in a row
- Closed at $3.22, -21.46% vs the prior close of $4.10. Day range $3.10–$4.16, opened at $4.10.
- Volume was 138.40K shares, 0.1x its 50-day average of 2.67M — lighter than usual.
- Price is -19.7% vs its 50-day average ($4.01) and -73.7% vs its 200-day average ($12.22).
- 52-week range $1.51–$59.70; today's close sits at 3% of that range, 94.6% below the 52-week high.
- That makes 5 straight losses.
APUS latest news & SEC filings
Every SEC filing by or about APUS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Oct 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Sep 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.03 — Change to shareholder rights.
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
Sep 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 21, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Aug 14, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$20.17M (prior year -$2.66M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$11.77 (prior year -$2.57) (loss widened vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Jul 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade APUS
- How much it moves: over the last 20 sessions the average daily move was 21.55% (largest 114.8%). That is a volatile stock.
- Liquidity: about 11.80M shares (≈$51.78M) trade per day on average.
- 52-week position: $4.39 vs a range of $1.51–$59.70 (5% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:10 on Jul 24, 2026
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Oct 13, 2026; 8-K Oct 1, 2026; 8-K Sep 29, 2026.
- Share count: 1.51M shares outstanding (Aug 12, 2026), -88.0% vs a year earlier — the company has been reducing its share count.
- Listing: NYSE · industry: Pharmaceutical Preparations.
APUS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 4.25 | 4.41 | 4.00 | 4.39 | 109.00K |
| Oct 14, 2026 | 4.60 | 4.81 | 4.25 | 4.58 | 235.30K |
| Oct 13, 2026 | 4.87 | 4.91 | 4.26 | 4.62 | 339.80K |
| Oct 12, 2026 | 5.43 | 6.04 | 4.97 | 5.20 | 1.39M |
| Oct 9, 2026 | 5.54 | 5.72 | 4.40 | 5.02 | 3.35M |
| Oct 8, 2026 | 6.43 | 6.50 | 5.21 | 5.51 | 1.11M |
| Oct 7, 2026 | 8.00 | 9.84 | 6.86 | 7.05 | 22.40M |
| Oct 6, 2026 | 4.91 | 8.39 | 4.71 | 7.13 | 43.84M |
| Oct 5, 2026 | 4.99 | 5.83 | 4.21 | 4.59 | 33.79M |
| Oct 2, 2026 | 4.10 | 4.16 | 3.10 | 3.22 | 138.40K |
| Oct 1, 2026 | 4.90 | 5.09 | 4.10 | 4.10 | 145.80K |
| Sep 30, 2026 | 5.04 | 5.25 | 4.72 | 5.00 | 190.10K |
| Sep 29, 2026 | 6.17 | 6.17 | 4.63 | 5.02 | 762.10K |
| Sep 28, 2026 | 6.33 | 6.50 | 5.56 | 6.39 | 858.80K |
| Sep 25, 2026 | 8.32 | 9.14 | 5.39 | 7.25 | 37.11M |
| Sep 24, 2026 | 6.99 | 8.74 | 4.61 | 4.92 | 87.85M |
| Sep 23, 2026 | 1.81 | 2.30 | 1.75 | 2.29 | 152.50K |
| Sep 22, 2026 | 1.65 | 2.00 | 1.61 | 1.85 | 132.40K |
| Sep 21, 2026 | 1.72 | 1.87 | 1.67 | 1.67 | 671.00K |
| Sep 18, 2026 | 1.68 | 2.10 | 1.63 | 1.77 | 1.34M |
About Apimeds Pharmaceuticals US
Apimeds Pharmaceuticals US (APUS) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in MATAWAN, NJ. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1894525.
APUS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Erik C. Emerson | Chief Executive Officer | Oct 17, 2025 |
| Christopher Kim | Chairman and CMO | Oct 17, 2025 |
| Elona Kogan | Director | Nov 13, 2025 |
| Jakap Koo | Director | Nov 13, 2025 |
| Carol A O'Donnell | Director | Nov 13, 2025 |
| Bennett Weintraub | Director | Nov 13, 2025 |
| Hankil Yoon | Director | Nov 13, 2025 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Erik C. Emerson | Chief Executive Officer | Oct 17, 2025 |
| Christopher Kim | Chairman and CMO | Oct 17, 2025 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
APUS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-6.00M | -0.55 | $-8.93M |
| Dec 31, 2024 | — | $-1.39M | -0.18 | $-733.53K |
| Dec 31, 2023 | — | $-777.69K | -0.17 | $-627.79K |
Latest balance sheet: total assets $127.62M, total liabilities $21.18M, cash $278.37K (as of Jun 30, 2026).
APUS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on APUS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.